Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (131-140 of 231) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survivalJuan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, et al.
British Journal of Haematology|August 20, 2013
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaMaría E Sarasquete, Joaquín Martínez-López, María C Chillón, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
American Journal of Hematology|December 9, 2021
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON studySosana Delimpasi, Maria Victoria Mateos, Holger W Auner, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Pageof 24

Showing results (131-140 of 231) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survivalJuan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, et al.
British Journal of Haematology|August 20, 2013
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaMaría E Sarasquete, Joaquín Martínez-López, María C Chillón, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
American Journal of Hematology|December 9, 2021
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON studySosana Delimpasi, Maria Victoria Mateos, Holger W Auner, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Pageof 24